Financials Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 19/02/2026 am IST			5-day change	1st Jan Change
43.45 ^USD	-0.53%		-8.74%	-6.66%

06/02	Certain Restricted Stock Units of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 6-FEB-2026.	CI
06/02	Certain Options of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 6-FEB-2026.	CI

Projected Income Statement: Crinetics Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	0.071	1.078	4.737	4.013	1.039	6.328	61.62	203
Change	-	1,418.31%	339.42%	-15.28%	-74.11%	509.07%	873.73%	229.49%
EBITDA ¹	-74	-106.8	-166.9	-221.5	-336.1	-470.5	-488.4	-391.3
Change	-	-44.29%	-56.3%	-32.72%	-51.72%	-39.99%	-3.8%	19.88%
EBIT ¹	-74.95	-107.7	-167.9	-222.6	-338.9	-524.3	-563.9	-419.4
Change	-	-43.69%	-55.88%	-32.6%	-52.22%	-54.73%	-7.55%	25.63%
Interest Paid	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-73.81	-107.6	-163.9	-209.3	-298.4	-472.7	-498.1	-370.3
Change	-	-45.83%	-52.28%	-27.7%	-42.55%	-58.42%	-5.37%	25.66%
Net income ¹	-73.81	-107.6	-163.9	-214.5	-298.4	-472.2	-497	-389.2
Change	-	-45.83%	-52.28%	-30.88%	-39.1%	-58.25%	-5.24%	21.69%
Announcement Date	30/03/21	30/03/22	28/02/23	28/02/24	27/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	-	-	-	-	1.078	3.131	0.439	0.458	0.709	2.679	0.988	0.346	-	0.64	0.399	-	-	0.361	1.031	0.143	4.74	7.587	11.09	15.79	23.25
Change	-	-	-	-	-	190.45%	-85.98%	4.33%	54.8%	277.86%	-63.12%	-64.98%	-	-	-37.66%	-	-	-	185.6%	-86.13%	3,214.69%	60.06%	46.15%	42.4%	47.22%
EBITDA ¹	-21.57	-22.69	-25.86	-27.57	-30.65	-33.59	-42.83	-43.21	-47.28	-47.7	-	-	-62.4	-73.06	-82.03	-87.03	-93.96	-110.5	-128.2	-141.6	-109.8	-113.4	-112.2	-119	-
Change	-	-5.23%	-13.95%	-6.63%	-11.17%	-9.57%	-27.52%	-0.88%	-9.42%	-0.89%	-	-	-	-17.08%	-12.29%	-6.09%	-7.96%	-17.59%	-16%	-10.47%	22.45%	-3.3%	1.1%	-6.08%	-
EBIT ¹	-21.79	-22.92	-26.09	-27.81	-30.89	-33.83	-43.04	-43.45	-47.56	-47.98	-53	-58.98	-62.66	-73.53	-82.78	-87.8	-94.74	-111.4	-129.1	-142.6	-141.5	-144.5	-146.8	-147.2	-143.6
Change	-	-5.17%	-13.84%	-6.59%	-11.08%	-9.52%	-27.25%	-0.95%	-9.44%	-0.89%	-10.46%	-11.29%	-6.24%	-17.35%	-12.59%	-6.06%	-7.91%	-17.58%	-15.89%	-10.44%	0.78%	-2.17%	-1.53%	-0.29%	2.44%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-21.64	-22.9	-26.1	-27.85	-30.79	-34.63	-42.38	-41.92	-44.99	-46	-50.98	-57.46	-55.9	-66.46	-74.06	-76.83	-80.6	-96.77	-115.6	-130.1	-130.6	-123.1	-126.3	-128.1	-124.5
Change	-	-5.82%	-13.95%	-6.73%	-10.57%	-12.45%	-22.38%	1.06%	-7.31%	-2.23%	-10.84%	-12.71%	2.72%	-18.9%	-11.43%	-3.74%	-4.9%	-20.07%	-19.49%	-12.5%	-0.4%	5.74%	-2.61%	-1.41%	2.78%
Net income ¹	-21.64	-22.9	-26.1	-27.85	-30.79	-34.63	-42.38	-41.92	-44.99	-46	-50.98	-57.46	-60.1	-66.93	-74.06	-76.83	-80.6	-96.77	-115.6	-130.1	-130	-123.2	-125.8	-126.9	-123.7
Change	-	-5.82%	-13.95%	-6.73%	-10.57%	-12.45%	-22.38%	1.06%	-7.31%	-2.23%	-10.84%	-12.71%	-4.59%	-11.37%	-10.65%	-3.74%	-4.9%	-20.07%	-19.49%	-12.5%	0.08%	5.23%	-2.1%	-0.86%	2.53%
Announcement Date	30/03/21	06/05/21	10/08/21	05/11/21	30/03/22	12/05/22	12/08/22	14/11/22	28/02/23	04/05/23	08/08/23	07/11/23	28/02/24	09/05/24	08/08/24	12/11/24	27/02/25	08/05/25	07/08/25	06/11/25	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Crinetics Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-171	-334	-334	-559	-1,355	-1,151	-1,182	-951
Change	-	-95.32%	0%	-67.37%	-142.4%	15.03%	-2.69%	19.54%
Announcement Date	30/03/21	30/03/22	28/02/23	28/02/24	27/02/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Crinetics Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	0.186	0.436	1.656	4.688	3.844	3.7	1.7	2.5
Change	-	134.41%	279.82%	183.09%	-18%	-3.75%	-54.05%	47.06%
Free Cash Flow (FCF) ¹	-62.21	-89.02	-116.9	-171	-229.8	-393	-357.3	-284
Change	-	-43.1%	-31.27%	-46.32%	-34.4%	-71.01%	9.08%	20.52%
Announcement Date	30/03/21	30/03/22	28/02/23	28/02/24	27/02/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Crinetics Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-1,04,232.39%	-9,905.38%	-3,523.31%	-5,519.81%	-32,345.43%	-7,434.23%	-792.53%	-192.7%
EBIT Margin (%)	-1,05,567.61%	-9,990.91%	-3,544.06%	-5,547.17%	-32,613.47%	-8,285.04%	-915.14%	-206.56%
EBT Margin (%)	-1,03,960.56%	-9,985.25%	-3,460.38%	-5,216.32%	-28,720.69%	-7,470.24%	-808.39%	-182.39%
Net margin (%)	-1,03,960.56%	-9,985.25%	-3,460.38%	-5,345.85%	-28,720.69%	-7,462.46%	-806.56%	-191.7%
FCF margin (%)	-87,623.94%	-8,258.26%	-2,466.98%	-4,261.03%	-22,118.77%	-6,210.24%	-579.9%	-139.88%
FCF / Net Income (%)	84.29%	82.7%	71.29%	79.71%	77.01%	83.22%	71.9%	72.97%
Profitability
ROA	-47.04%	-40.28%	-46.62%	-43.45%	-28.83%	-	-	-
ROE	-51.61%	-42.98%	-50.57%	-50.16%	-32.02%	-35.36%	-35.85%	-26.2%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	261.97%	40.45%	34.96%	116.82%	369.97%	58.47%	2.76%	1.23%
CAPEX / EBITDA (%)	-0.25%	-0.41%	-0.99%	-2.12%	-1.14%	-0.79%	-0.35%	-0.64%
CAPEX / FCF (%)	-0.3%	-0.49%	-1.42%	-2.74%	-1.67%	-0.94%	-0.48%	-0.88%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	5.548	8.636	5.871	7.91	14.26	14.64	12.38	10.51
Change	-	55.67%	-32.02%	34.72%	80.24%	2.69%	-15.44%	-15.11%
EPS ¹	-2.42	-2.8	-3.15	-3.69	-3.69	-5.016	-4.972	-3.862
Change	-	-15.7%	-12.5%	-17.14%	0%	-35.93%	0.86%	22.32%
Nbr of stocks (in thousands)	32,922	47,157	53,810	66,799	92,738	1,02,512	1,02,512	1,02,512
Announcement Date	30/03/21	30/03/22	28/02/23	28/02/24	27/02/25	-	-	-